Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response
Massimiliano Bonifacio,
Gianni Binotto,
Elena Maino,
Elisabetta Calistri,
Luciana Marin,
Luigi Scaffidi,
Luca Frison,
Federico De Marchi,
Mauro Krampera,
Giampiero Semenzato,
Renato Fanin,
Achille Ambrosetti,
Mario Tiribelli
Affiliations
Massimiliano Bonifacio
Department of Medicine, Section of Hematology, University of Verona, Italy
Gianni Binotto
Padua School of Medicine, Department of Medicine, Hematology and Clinical Immunology, Padua, Italy
Elena Maino
Hematology Unit, Dell’Angelo Hospital, Venezia-Mestre, Italy
Elisabetta Calistri
Hematology Unit, Ca’ Foncello Hospital, Treviso, Italy
Luciana Marin
Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Italy
Luigi Scaffidi
Department of Medicine, Section of Hematology, University of Verona, Italy
Luca Frison
Padua School of Medicine, Department of Medicine, Hematology and Clinical Immunology, Padua, Italy
Federico De Marchi
Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Italy
Mauro Krampera
Department of Medicine, Section of Hematology, University of Verona, Italy
Giampiero Semenzato
Padua School of Medicine, Department of Medicine, Hematology and Clinical Immunology, Padua, Italy
Renato Fanin
Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Italy
Achille Ambrosetti
Department of Medicine, Section of Hematology, University of Verona, Italy
Mario Tiribelli
Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Italy
